Introduction
Cystic fibrosis (CF) is the most common monogenic disorder in Caucasians. In CF, the dysfunction of the CF transmembrane conductance regulator (CFTR) results in a complex phenotype. Individuals with CFTR mutations have abnormalities in chloride and sodium ion transport across epithelial membranes, contributing to the development of progressive obstructive airway disease, malabsorption, sinusitis, liver dysfunction and CF-related diabetes. As the disease progresses, the airways of patients with CF become infected and colonized with a variety of opportunistic pathogens, predominantly Pseudomonas aeruginosa. 1 At present, the foremost cause of morbidity and mortality in CF is respiratory failure due to persistent pulmonary infections with P. aeruginosa, intense neutrophil-dominated airway inflammation, and progressive bronchiectasis and lung damage.
A number of studies support the premise that the lungs of CF patients have an abnormal, upregulated proinflammatory cytokine profile. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Whether the mechanism of the altered immune response in CF is directly or indirectly due to CFTR mutations and/or other polymorphisms present in patients with CF is not known. However, a body of evidence supports the presence of a relative interleukin (IL)-10 deficiency in patients with CF. 10, 12 IL-10 inhibits the production of cytokines by T lymphocytes and potently suppresses macrophage production of activating and/or chemotactic cytokines, including the polymorphonuclear neutrophil chemoattractant IL-8 and other nuclear factor-kB-dependent cytokines, including tumor necrosis factor (TNF)-a, IL-1b and IL-6. [13] [14] [15] [16] IL-10 may also facilitate the resolution of lung inflammation by promoting apoptosis of polymorphonuclear neutrophils. 17 Deficiency of IL-10 production, as shown by studies in IL-10-deficient transgenic (IL-10T) mice, 18 leads to greater neutrophil recruitment, more severe weight loss and increased areas of lung inflammation when compared with wild-type mice with analogous chronic endobronchial P. aeruginosa infection. [19] [20] [21] These findings are similar to those of P. aeruginosainfected CF mice. [21] [22] [23] [24] IL-10T mice repeatedly exposed to mucoid P. aeruginosa have higher mortality rates and more severe lung pathology when compared with C57BL/6 controls similarly infected; 25 in addition, IL-10T mice have a prolonged inflammatory response to acute P. aeruginosa challenge. 26 Research shows that treatment with IL-10 reduces neutrophil and leukocyte recruitment, decreases proinflammatory cytokine production, and causes an increase in weight loss and tissue injury in the airways of sensitized animals following antigen exposure or P. aeruginosa challenge, 19, 21, [27] [28] [29] [30] supporting the use of IL-10 in ameliorating inflammation.
Gene transfer of IL-10 conveys the advantage of long-term gene expression, an inherent feature of adenoassociated virus (AAV)-based vectors. [31] [32] [33] These vectors have a proven safety profile and the ability to elicit a minimal inflammatory response in comparison with other gene transfer agents. [34] [35] [36] [37] To increase lung-specific delivery and promote high levels of gene expression, we used an AAV5 pseudotyped vector for efficient airway transduction [38] [39] [40] and the CMV (Cytomegalovirus)/chicken-b-actin hybrid (Cb) promoter, a promoter with robust activity in the murine lung. 41 Using these elements, we hypothesized that AAV-based gene transfer of IL-10 would result in high levels of lung-specific IL-10 expression, ameliorating the excessive response in the lung without systemic immunosuppression. In this study, we characterize AAV5.CbmIL10 in an IL-10T mouse model of chronic P. aeruginosa lung infection to determine whether IL-10 gene delivery and expression specifically reduces the proinflammatory response in the lungs.
Results
AAV5.Cb-mIL10 and PBS-treatment result in similar percentage weight loss in IL-10T mice infected with P. aeruginosa-laden beads Interleukin-10T mice were intratracheally inoculated with 1 Â 10 12 vector genomes of AAV5.Cb-mIL10 or PBS. Six weeks later, the mice that received AAV5.CbmIL10 were infected with 5 Â 10 6 colony-forming units (cfu) of P. aeruginosa-laden beads (n ¼ 5). Mice that received PBS were either given sterile beads (n ¼ 4) or infected with 5 Â 10 6 cfu of P. aeruginosa-laden beads (n ¼ 6). Mice were euthanized after 3 days. Each experiment was repeated twice.
To ensure that AAV5.Cb-mIL10 did not affect mouse weight, the mice were weighed before the administration of AAV5.Cb-mIL10 or PBS and 6 weeks later before P. aeruginosa-laden bead infection. There was no significant difference in the percentage weight gain between the groups (P40.05).
The mice were weighed a second time before the administration of P. aeruginosa-laden beads and 3 days later before being euthanized. The average pre-infection weight of the mice receiving AAV5.Cb-mIL10 (n ¼ 5) was 23.3 g with mice experiencing an average percentage weight loss of 16.4±9.9 over the 3 days after P. aeruginosa infection. This profile was similar to the mice in the PBS group infected with P. aeruginosa (n ¼ 6); the initial weight was 22.2 g with mice experiencing an average percentage weight loss of 22.4±1.3. Mice that were not infected (received sterile beads as a control for surgery, n ¼ 4) had an average initial weight of 22.6 g and lost an average body weight of 5.3 ± 1.6%. There was no significant difference in the percentage weight loss between AAV5.Cb-mIL10 and PBS mice infected with P. aeruginosa-laden beads (P40.05); statistical difference could not be obtained from mice receiving sterile beads due to the small sample size.
Intratracheal administration of AAV5.Cb-mIL10 produces significant levels of IL-10 protein in the lungs Interleukin-10 expression following AAV5.Cb-mIL10 administration in the lungs of IL-10T mice infected with P. aeruginosa was measured to verify gene transfer and expression efficiency. In the AAV5.Cb-mIL10-treatment group, mice were infected with 5 Â 10 6 cfu of P. aeruginosa-laden agarose beads by intratracheal inoculation. Mice receiving PBS were either given sterile beads or infected with 5 Â 10 6 cfu of P. aeruginosaladen agarose beads. Three days later, the mice were euthanized and blood and bronchoalveolar lavage fluid, lung tissue and blood were collected from each animal.
The administration of AAV5.Cb-mIL10 successfully resulted in the production of IL-10 as measured in the epithelial lining fluid (average, 25 000 pg/ml) and lung homogenate (average, 12 000 pg/gram-lung) (Figure 1 ). IL-10 production was also measured in the serum to determine whether production was systemic. IL-10 was undetectable in the serum of mice in all treatment groups (data not shown), thus confirming localized secretion of IL-10 from the AAV5.Cb-mIL10 vector.
AAV5.Cb-mIL10 mediates IL-10 protein expression in the alveoli
To identify the specific cells responsible for protein expression, an immunostaining protocol for IL-10 was developed using paraffin-embedded lung sections. Positive IL-10 staining was evident in lung sections from P. aeruginosa-infected IL-10T mice that received AAV5.Cb-mIL10 (Figure 2a ). In contrast, there was no IL-10 staining in the lung tissue harvested from IL-10T mice that received PBS (Figure 2b ). These data confirm that resident alveolar cells had been successfully infected with the IL-10 vector and are responsible for IL-10 protein production.
AAV5.Cb-mIL10 produces a significant decrease in proinflammatory cytokine levels in the lungs
The lung homogenates from IL-10T mice that received AAV5.Cb-mIL10 or PBS and were infected with P. aeruginosa were analyzed for cytokine levels. AAV5.Cb-mIL10 reduced chemokine levels; a 9-fold reduction in KC and a fourfold reduction in macrophage inhibitory protein (MIP)-1a were observed in mice treated with AAV5.Cb-mIL10 as compared with those mice treated with PBS ( Figure 3 ). There was also a fivefold reduction of proinflammatory cytokine levels of IL-1b and a 0.5-fold reduction of TNF-a in AAV5.CbmIL10-treated mice as compared with those levels in PBS-treated mice. Chemokines and cytokines in the blood and bronchoalveolar lavage fluid, converted to epithelial lining fluid levels, demonstrated a similar profile to that seen in the lung homogenate. Proinflammatory cytokines (IL-1b, KC and MIP-1a) were reduced in the epithelial lining fluid of mice receiving AAV-IL10; however, the amount was not found to be statistically significant because of the number of mice in this cohort not being large enough to carry out statistical analysis (data not shown). To determine if the dramatic reduction in lung proinflammatory cytokines had a systemic effect, we measured circulating proinflammatory cytokine concentrations in the serum and did not observe a decrease (data not shown). This pathology corroborates our cytokine findings and supports our hypothesis that AAV5.Cb-mIL10 can effectively reduce inflammation in P. aeruginosa-infected lungs. 12 vector genomes of AAV5.Cb-mIL10. After 6 weeks, AAV5.Cb-mIL10-treated mice were intratracheally infected with 5 Â 10 6 cfu of P. aeruginosa-laden beads, whereas PBS-treated mice were infected with P. aeruginosa-laden beads or sterile beads. Untreated mice did not receive the vector, PBS, or agarose beads. Mice were sacrificed 3 days later. IL-10 protein levels were measured in the epithelial lining fluid (ELF, ', p/g ml) and lung homogenate (LH, &, pg/g-lung). **Po0.005 compares PBS and AAV5.Cb-mIL10 treatments in IL-10 levels in the epithelial lining fluid and lung homogenate, respectively. Data shown are average ± s.d. for three or more animals in each group from two experiments.
IL-10
gene transfer attenuates pseudomonas pneumonia SM Buff et al
Discussion
Interleukin-10 balances the proinflammatory response and serves to limit and terminate the cascade of inflammatory cytokines triggered by nuclear factor-kB activation. By regulating cytokine secretion and the differentiation and proliferation of many immune cells such as T, B, natural killer, antigen-presenting cells, mast cells and granulocytes, IL-10 helps maintain immune homeostasis. Stimulation of the IL-10 receptor regulates signaling pathways, including JAK/STAT3, PI 3-kinase, MAPK and suppressor of cytokine signaling, 42 by selectively inhibiting STAT 3 transcription, rather than generally blocking nuclear factor-kB activation. 43 IL-10 may also decrease myeloid cells and prevent cell-to-cell communication between macrophages and T cells, resulting in decreased production of proinflammatory cytokines and cytotoxic factors. 44 Through these mechanisms, IL-10 reduces the production and release of TH-1 cytokines including IL-2, IL-6, IL-8 and TNF-a. In CF, the documented decrease of IL-10 production is thought to contribute to the excessive inflammation present in the airway during active and chronic infection. 2, 3 Supporting this theory are studies of chronic P. aeruginosa infection in IL-10T and CFTR knockout mice, demonstrating dramatic weight loss, greater polymorphonuclear neutrophil infiltration and higher concentrations of proinflammatory cytokines following infection compared with wild-type mice. [19] [20] [21] [22] [23] [24] In this study, we carried out intratracheal inoculation with AAV5.Cb-mIL10 6 weeks before infection using a chronic P. aeruginosa model in IL-10T mice. IL-10 was expressed in the alveoli and produced at significantly higher levels in the epithelial lining fluid and lung homogenate in vector-treated mice compared with mice that received PBS. IL-10 production correlated with a significant decrease in proinflammatory cytokines, IL-1b, KC and MIP-1a, as well as a decrease in TNF-a and a reduction in inflammation-associated lung pathology (neutrophil influx and lung consolidation). This finding corroborates the results found by others when IL-10 was administered as recombinant protein. 19, 21, 29 In a chronic P. aeruginosa infection in CD-1 mice, Chmiel et al. 19 found that intraperitoneal administration of recombinant IL-10 (rIL-10) resulted in increased survival, fewer neutrophils in the bronchoalveolar lavage (BAL), decreased areas of lung inflammation and no decrease in bacterial burden when compared with placebo-treated mice. A study was also carried out with intraperitoneal injection of rIL-10 to CFTR knockout mice resulting in decreased T-cell costimulatory molecule B7 and poor co-stimulatory activity of bronchoalveolar macrophages. 30 As bronchoalveolar macrophages from patients with CF have been shown to actively produce the proinflammatory cytokines which are elevated in CF BAL, 3, 10 treatment with IL-10 may suppress the synthesis of these proinflammatory cytokines and alter T-cell responses. Further supporting our results with AAV5.Cb-mIL10, Sawa et al.
29 administered rIL-10 intraperitoneally before or after acute P. aeruginosa infection in Balb/c mice, finding decreased lung injury and mortality and a decreased inflammatory response. rIL-10 was also administered subcutaneously in an acute model using intratracheal lipopolysaccharide (LPS) challenge in CF mice, resulting in a significant decrease of polymorphonuclear neutrophils and TNF-a that correlated with decreased nuclear factor-kB activity and increased IkBa. 21 This study also addressed current barriers to sufficient gene expression by AAV gene transfer through employing an AAV5 pseudotyped vector, which binds to apically expressed receptors (2,3-linked sialic acid and the platelet-derived growth factor) [38] [39] [40] and a potent promoter (Cb), previously demonstrated to be highly effective in the murine lungs. 41 Despite high levels of IL-10 protein expression in the lungs of mice receiving AAV5.Cb-mIL10, blood levels of proinflammatory cytokines and IL-10 from mice receiving AAV5.Cb-mIL10 were not significantly different from those measured in PBS-treated mice. This finding supports a localized IL-10 effect, an important safety feature because IL-10 leakage into the circulation could mediate systemic immunosuppression or even become immunostimulatory at high IL-10 gene transfer attenuates pseudomonas pneumonia SM Buff et al systemic doses; 45 rIL-10 administered systemically was previously found to attenuate both local and systemic effects. 19 There were several limitations in this study. Instead of using CFTR knockout mice, which are difficult to breed, we used the readily available IL-10T-mouse model. It is important to note that there are strong similarities between the IL-10T and CFTR knockout mice in response to both chronic and acute P. aeruginosa lung infections. This response is characterized by greater neutrophil recruitment, more severe weight loss and increased areas of lung inflammation when compared with wild-type mice, [19] [20] [21] [22] [23] [24] 26 suggesting an important role for IL-10 in regulating the inflammatory response to P. aeruginosa. As the IL-10T mice were created by a targeted mutation of the IL-10 gene, the result is a dramatic deficiency in, but not elimination of, IL-10 production. IL-10T mice do produce background levels of IL-10, demonstrated in our PBS-treated mice infected with P. aeruginosa ( Figure 1) ; however, this level was significantly less than the levels of IL-10 produced by AAV5.Cb-mIL10 (Po0.005).
The model of chronic infection using P. aeruginosaladen agarose beads occurred over a short period of time (3 days) and seems counterintuitive as a chronic model; however, this commonly used approach to chronic lung infection is the most appropriate in vivo representation in experimental models of CF. In non-CF mice, infection with P. aeruginosa-laden beads can persist for up to 28 days, 22, 46, 47 whereas CFTR knockout mice appear to have more severe mortality and inflammation, characterized by high levels of proinflammatory mediators (TNF-a, KC and MIP-2) 3 days after exposure to the beads. Between days 3 and 7 after infection with P. aeruginosa-laden beads in CF mice, the process of bacterial killing is Figure 4 Inflammation-associated pathology is reduced in AAV5.Cb-mIL10-treated mice. Anesthetized mice were intratracheally injected with PBS or 1 Â 10 12 vector genomes of AAV5.Cb-mIL10. After 6 weeks, AAV5.Cb-mIL10-treated mice were intratracheally infected with 5 Â 10 6 cfu P. aeruginosa-laden beads while PBS-treated mice were infected with P. aeruginosa-laden beads or sterile beads. Mice were sacrificed 3 days later. Lungs were collected and fixed in paraformaldehyde, then sectioned and hematoxylin and eosin stained. (a, b) AAV5.Cb-mIL10 with P. aeruginosa-laden beads, (c, d) PBS with P. aeruginosa-laden beads, and (e, f) PBS with sterile beads. Magnifications are Â 4 (a, c, e) and Â 10 (b, d, f). Observations represent the findings from three or more animals from two experiments.
IL-10 gene transfer attenuates pseudomonas pneumonia SM Buff et al impaired and on day 7, 80% of the mice die compared with wild-type mice who experience a 50% mortality rate. 22, 48 A euthanized date of 3-4 days is documented to be optimal for the analysis of cytokines and lung pathology 49 , and were the measures we used to characterize the therapeutic potential of AAV5.Cb-mIL10. Given the optimal expression time of AAV-based vectors (weeks) and the susceptibility of IL-10T mice to P. aeruginosa infection (days), post-infection administration of the therapeutic was not possible; however, the significant proinflammatory cytokine decrease (Po0.005) and lung pathology resolution strongly supports the therapeutic potential of IL-10 delivered with an AAV vector.
The authors did not use a sham AAV vector to ensure that the AAV did not affect P. aeruginosa infection or innate IL-10 production. Although AAV-mediated gene transfer leads to the development of antibodies against the vector capsid, possibly preventing vector re-administration, the lack of inflammatory responses documented in numerous in vivo gene transfer models employing AAV vectors suggests that these agents do not interact significantly with the innate immune system. 32 Studies in non-human primates with AAV-CFTR show that the vector does not result in an increase in proinflammatory cytokines and neutrophil influx as measured in the blood and bronchoalveolar lavage fluid. 32 Furthermore, AAV modulation of the immune system would be anti-inflammatory and, if anything, provide a more conducive environment for P. aeruginosa infection. The resolution of lung pathology and percentage weight loss (P40.05) in AAV5.Cb-mIL10-treated mice does not support this theory. In addition, studies in murine models have shown that AAV-GFP has the same response as PBS when measuring percentage weight loss and neutrophil migration (T Ferkol, unpublished data), supporting our use of PBS as a negative control.
Blood and spleen homogenates were not cultured in this study, although we have cultured them in similar studies and infection was not found. We observed that mice receiving AAV5.Cb-mIL10 before P. aeruginosa infection appeared to be healthier (more active, experienced less respiratory distress and were better groomed) than mice that received PBS. The fact that high levels of IL-10 do not promote bacteremia is supported by studies that show chronic P. aeruginosa infection in IL-10T and CF-mice models have no difference in bacterial burden when compared with wild-type mice. 22 In addition, the bacterial burden following systemic IL-10 administration is unchanged in IL-10T and CF mice. 19 The fact that the bacterial burden does not change as a result of AAV5.CbmIL10 administration will not result in an adverse effect on the therapeutic potential of AAV5.Cb-mIL10. The therapeutic potential of AAV5.Cb-mIL10 is the modulation of an excessive proinflammatory response, demonstrated by a decreased proinflammatory cytokine profile. IL-10 treatment is not likely to cause bacterial proliferation because previous studies found that anti-inflammatory therapeutics, such as ibuprofen and glucocorticoids, do not cause an increase in bacterial burden; the inflammatory response is decreased from a heightened state, but not decreased to a state of immunosuppression. [50] [51] [52] This therapeutic effect is demonstrated by the treatment of CF patients with anti-inflammatory therapeutics, slowing the progression of lung disease, not exacerbating infection. The goal of anti-inflammatory treatment in patients with CF is not specifically to reduce P. aeruginosa infection, but to decrease the pathologic response that results in tissue injury and respiratory failure. In fact, the persistent inflammation in the CF lung is the major cause of progressive lung injury and damage, leading to decreased pulmonary function and death. Studies have shown that patients with CF have an inherent pro-inflammatory environment in the lungs and an excessive response to bacterial infection. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] This study continues to lay the foundation towards characterizing AAV-based IL-10 delivery as a viable therapeutic for CF lung disease. In future studies, it will be important to further define the molecular pathways of AAV-IL10-based immunomodulation and persistence, as well as physical barriers to vector entry and expression. As we and other authors speculate, the IL-10 effects are most likely due to the regulation of nuclear factor-kB and inhibition of proinflammatory cytokine production; however, these effects have not been specifically studied for AAV-based IL-10 gene transfer. The immune response to the AAV vector and the duration of AAV-mediated IL-10 gene expression needs to be examined to provide implications for vector administration and the role IL-10 expression may afford. Although the duration of IL-10 gene expression in the mouse lung was not measured in this study and has not been recorded specifically for IL-10, Sumner-Jones et al. 53 investigated transgene expression following delivery of rAAV5/5 vectors to the mouse respiratory tract and found transgene expression in the epithelium lining of the nose for at least 32 weeks and in the lung for at least 52 weeks. Furthermore, because our therapeutic gene, IL-10, is produced by a variety of cells and is a secreted protein, it has more available targets and may demonstrate its anti-inflammatory effects in sites removed from the successfully transduced cells.
In addition, the widely used P. aeruginosa-laden bead model requires a euthanized date of 3-4 days for optimal analysis of cytokines and lung pathology 49 and does not allow post-infection administration of AAV-IL10. The delayed gene expression of AAV over several weeks could be modulated by proteasome inhibitors, although other models of chronic infection may be necessary to compare pre-and post-infection characteristics of AAV5.Cb-mIL10 and advance this therapeutic from the bench to the bedside, achieving translational research. Moreover, addressing the physical barrier of mucus in the lung will be essential and may be ameliorated by mimicking the current treatment regimen for that patients with CF use. In coordination with airway clearance, patients take aerosolized medications to open the airway and liquefy the mucus; these include bronchodilators, anti-inflammatory therapeutics and mucolytic agents such as dornase alpha (Pulmozyme, Genentech, San Francisco, CA, USA) which contains DNase. Although mucolytic agents are not viable for AAV delivery because they disrupt the integrity of the vector, airway clearance has been used in AAV clinical trials to increase vector delivery to the lung.
In recent decades, much progress has been made in the treatment of CF, contributing to a longer life span and less morbidity for patients with CF. However, airway inflammation and infection continue to be problematic for the majority of patients, leading to progressive airway obstruction, lung damage and eventually death. The role of inflammation in the pathogenesis of CF has IL-10 gene transfer attenuates pseudomonas pneumonia SM Buff et al been controversial, but the majority of current evidence supports the hypothesis that airway inflammation in CF is exaggerated and pathological.
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Although antiinflammatory treatments for CF airway disease have been associated with modest improvements in lung health, none have achieved a high rate of success, and several carry the risk of significant side effects. Therefore, the development of safer and more effective antiinflammatory therapies continues to be essential. In this study, we prove our hypothesis that in a chronic P. aeruginosa infection model, AAV5.Cb-mIL10 mediates high levels of lung-specific IL-10 expression, resulting in a reduction of proinflammatory cytokines with no systemic leakage. The anti-inflammatory activity of AAV5.Cb-mIL10 is an important step toward finding new, effective therapies for inflammation in CF and validating the use of AAV gene transfer to alter the local proinflammatory immune response in the lung. Future studies should analyze the duration of AAV-mediated gene expression, shown for some transgenes to persist for 1.5 years in animal models, [54] [55] [56] [57] a feature that is clinically relevant for a population of patients with CF who receive multiple therapies a day. 58 
Materials and methods

Mice
Eight-week old IL-10-deficient transgenic (IL-10T) mice (C57BL/6 background) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and were acclimated to their environment for at least 3 days before use. Mice were fed autoclaved or irradiated Harlan Teklad Sterilizable Rodent Blox 8656 (Harland Teklad, Indianapolis, IN, USA) and bedded on autoclaved 1/8 00 corn-cob bedding and corn-husk nesting material (Harland Teklad). Mice were housed, 2-4, in Micro-Isolator Top Flow Ventilated cages (Tecniplast, Exton, PA, USA) in ventilated racks. All procedures were approved by the Institutional Animal Use and Care Committee (IACUC) at MUSC.
Recombinant AAV-IL-10 vector
The murine cDNA for the cytokine IL-10 was cloned into the pAAV2.Cb plasmid containing AAV-2 inverted terminal repeats, a CMV/chicken-b-actin hybrid promoter, including an intron, and the SV40 polyadenylation region. 59 To facilitate pseudotyping, pAAV.Cb-mIL10 was co-transfected with pXYZ5, an adenoviral helper plasmid with AAV2 rep/AAV5 cap. 60 Anion-exchange chromatography was used to purify the AAV5 pseudotyped vector, and the dot-blot assay was used to determine the titer of rAAV virions harboring vector genomes. The pseudotyped packaged vector was then designated as AAV5.Cb-mIL10.
P. aeruginosa-laden bead preparation
The mucoid P. aeruginosa isolate, PA 15719, was obtained from the sputum of a patient with CF using a protocol approved by the Institutional Review Board at MUSC. Bacteria were maintained as glycerol stocks and stored at À80 1C. Bacteria-impregnated agar beads were prepared as described by van Heeckeren et al. 22, 49 with minor modifications. Briefly, an inoculation loop was used to collect a sample of frozen mucoid P. aeruginosa stock, streaked for isolation on a tryptic soy agar plate, and incubated at 37 1C overnight. One colony was picked from the plate and used to inoculate 50 ml tryptic soy broth in a 125-ml Erlenmeyer flask. The flask was placed in a 37 1C incubator and shaken overnight. A 0.1 ml aliquot of the culture was used to inoculate a second flask of 50 ml tryptic soy broth in a 125-ml Erlenmeyer flask. Bacteria were grown to late log phase, shaking, in a 37 1C incubator. The bacterial culture was concentrated by centrifugation, resuspended in 10 ml tryptic soy broth and 5 ml of the suspension added to warm (50 1C) 2% low-melting agarose (type 1 low electroendosmosis (EEO); Sigma-Aldrich, St. Louis, MO, USA) in PBS. The bacteria-agar mixture was added to warm (50 1C) heavy mineral oil (0122-4, Fisher) containing a stir bar and stirred rapidly at room temperature for 6 min, followed by cooling with slow additions of ice over a 10-min period. The agar beads were transferred to a separatory funnel; the mineral oil removed and washed one time with 0.5% sodium deoxycholate, one time with 0.25% sodium deoxycholate, and four times with PBS. The P. aeruginosa-laden agarose beads were collected and allowed to settle. Additional liquid was removed to obtain a final volume of 75% beads and homogenized using a Kinematica Polytron PT10/35 homogenizer for 4 min at high speed to obtain beads predominantly 100-120 mm in diameter. The size of the beads was measured microscopically before and after homogenization. Using serial dilutions, quantitative bacteriology was carried out on an aliquot of the homogenized bead slurry to determine bacterial concentration in cfu per milliliter. Sterile agar beads were prepared by the same method, without the addition of P. aeruginosa culture, and were verified for sterility by serial dilutions plated on tryptic soy agar plates. The homogenized bead slurries for both preps were prepared the day before inoculation of the mice, stored at 4 1C and concentration of bacteria calculated on the day of inoculation.
Assessment of weight loss
Body weight was measured in all mice before PBS or AAV5.Cb-mIL10 administration, before infection with sterile beads or P. aeruginosa-laden beads (6 weeks later), and at time of euthanized (3 days after infection). A record was made of any hunching, poor grooming, fatigue or increased respiratory effort following inoculation with agarose beads.
Intratracheal inoculation
For the preparation of intratracheal inoculation, mice were sedated through inhalation of isoflurane. A transverse cervical incision was made, and the trachea was exposed and intubated with a sterile, flexible 21-G SURFLO winged infusion set (Terumo Corporation, Tokyo, Japan) attached to a 1.0-ml syringe. A total volume of 30 ml containing 1 Â 10 12 vector genomes AAV5.Cb-mIL10 or PBS was injected into the trachea. All incisions were closed by suture. Six weeks after treatment with AAV5.Cb-mIL10 or PBS, the mice underwent intratracheal inoculation with sterile agarose beads or P. aeruginosa-laden beads. Anesthesia and intratracheal inoculation were carried out as before, with the inoculation of 50 ml of sterile beads or 5 Â 10 6 cfu of P. aeruginosaladen beads.
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Collection and processing of samples
At 3 days following sterile bead or P. aeruginosaladen bead infection, the mice were anesthetized with isoflurane and euthanized by exsanguination. Blood and bronchoalveolar lavage (BAL) fluid were collected. For the BAL collection, the trachea was isolated by blunt dissection. An incision was made in the upper portion of the trachea, which was cannulated with a 21-G shielded intravenous catheter (BD Bioscience, San Jose, CA, USA) attached to a 5 ml syringe. The alveoli were washed three times, each with 1 ml PBS. The volume of bronchoalveolar lavage fluid recovered was approximately 1-2 ml. Lungs were collected and weighed for histology and cytokine analysis of lung homogenate. For histology, the lungs were inflated and fixed with 4% paraformaldehyde, whereas for lung homogenization, the lungs were immediately submerged in liquid nitrogen and stored at À80 1C.
To obtain homogenate cytokine values, the lungs were thawed and washed in 0.5 ml cell wash buffer (Bio-Rad, Hercules, CA, USA). In all, 1 ml of cell lysis buffer (Bio-Rad) was added to each lung, which was then homogenized for 60 s at high speed using a Kinematica Polytron PT10/35 homogenizer (Brinkmann Instruments, Westbury, NY, USA). The homogenized lung samples were frozen at À80 1C, thawed on ice, and sonicated in ice-cold water. They were centrifuged at 1500 g at 4 1C for 10 min; the supernatant was aspirated and the homogenate stored at À80 1C. Cytokine analysis was carried out within 24 h of homogenization.
Measurement of cytokine levels
Cytokine levels in the serum, BAL and lung homogenate were measured using a customized Bio-Plex cytokine kit (Bio-Rad) containing detection for IL-1b, TNF-a, IL-10, KC and MIP-1a. Analysis was conducted using the BioPlex multiplex suspension array system (Bio-Rad) per the company's protocol. Each sample was performed in duplicate. Epithelial lining fluid values were obtained through correction of the BAL dilution using a ratio of urea nitrogen concentrations in the airway fluid and in the serum by the enzymatic urea nitrogen (blood urea nitrogen) procedure (Stanbio, Boerne, TX, USA). Homogenate levels were standardized by lung weight for a final value of picogram per gram of lung.
Histological analysis
After the lungs were fixed in 4% paraformaldehyde for 48 h, they were embedded in paraffin and cut in 5 mm step-sections. The step-sections were left unstained (for immunohistochemistry) or stained with hematoxylin and eosin using standard techniques.
Immunohistological staining protocol
Five mm lung paraffin sections were soaked in Hemo-de for 10 min followed by rehydration in graded alcohol (100, 80, 40 and 20%) and water, each for 5 min. The sections were blocked with universal blocking solution (KPL, Gaithersburg, MD, USA) for 30 min at 25 1C and rinsed with water and Tris buffer. Then, the sections were blocked with goat serum at 25 1C for 15 min and incubated with rat anti-mouse IL-10 monoclonal antibody (1:1000 dilution; BD PharMingen, San Diego, CA, USA) overnight at 4 1C in a humidity chamber. The next day, the sections were washed in Tris buffer and incubated with biotinylated goat anti-rat IgG-horseradish peroxidase (1:100 dilution; BD PharMingen) at 25 1C for 1 h. The sections were further incubated with HRPstreptavidin (KPL) for 30 min at 25 1C and then incubated with true blue substrate solution (KPL) for 10 min at 25 1C. After being washed in water and counter-stained in orcein (KPL) for 3 min, the sections were dehydrated in graded alcohol and soaked in Hemode for 10 min.
Statistical analysis
Data are presented as average ± s.d. Change in body weight is expressed as the percentage of weight lost from the original weight 3 days before inoculation. Statistical analysis of percentage weight loss and cytokine levels were determined by unpaired, two-tailed Student's t test using the GraphPad InStat statistics software program (GraphPad Software, San Diego, CA, USA). Welch correction was applied when s.d. were significantly different. For all data sets, P-values o0.05 were determined to be statistically significant.
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